May 25, 2026 —
Eli Lilly reported early clinical data showing that the highest dose of VERVE-102, its investigational gene-editing therapy for cholesterol reduction, lowered LDL cholesterol by up to 62% in a Phase 1 clinical trial. The therapy is being developed as a potential single-dose treatment for patients with high LDL cholesterol who remain at elevated risk of cardiovascular disease.
VERVE-102 entered Lilly’s pipeline through the company’s approximately $1 billion acquisition of Verve Therapeutics, underscoring the growing interest among major pharmaceutical companies in gene-editing medicines that could replace lifelong chronic therapies. The program reflects a broader shift in genetic medicine from rare disease applications toward large chronic disease areas such as cardiovascular prevention.
Unlike conventional cholesterol-lowering therapies, including daily statins or regularly administered PCSK9 inhibitors, VERVE-102 is designed to deliver a durable reduction in LDL cholesterol after a single infusion. The therapy uses lipid nanoparticle delivery to package a messenger RNA encoding an adenine base editor, together with a guide RNA targeting the PCSK9 gene, a key regulator of LDL cholesterol.
A central feature of VERVE-102 is its liver-targeted delivery system. The therapy uses Verve’s proprietary GalNAc-LNP technology, in which a GalNAc ligand is incorporated into the LNP to support uptake by liver cells through receptors such as the asialoglycoprotein receptor or the low-density lipoprotein receptor. By directing the base-editing machinery to hepatocytes, the therapy aims to edit PCSK9 at its source and produce a long-lasting reduction in circulating LDL cholesterol.
VERVE-102 also incorporates a different ionizable lipid from Verve’s earlier candidate, VERVE-101, with the goal of improving the safety profile of the LNP delivery system. This distinction is important because safety, tolerability, off-target editing, and delivery-related immune or inflammatory effects remain key considerations for gene-editing therapies intended for broad cardiovascular populations.
According to Lilly, patients receiving the highest dose in the Phase 1 study experienced LDL reductions of up to 62%. While the result is preliminary, it strengthens the rationale for further development of one-time gene-editing approaches in cardiovascular disease, particularly for patients who struggle with long-term adherence or remain inadequately controlled on existing therapies.
Larger and longer-term studies will still be needed to confirm the durability, safety, and real-world clinical benefit of VERVE-102. If successful, the therapy could represent an important step toward a new treatment model for cardiovascular prevention: a one-time molecular intervention designed to provide sustained cholesterol lowering by editing the underlying genetic pathway.
